EXHIBIT 99.01

Shire Pharmaceuticals Group plc
Hampshire International Business Park
Chineham Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com

Press Release

12 April 2005

Shire Pharmaceuticals Group plc (the "Company")

The issuer clarifies that the Additional Listing announcement released on 12 April 2005, at 07:01hrs contains an error. Application has been made to the UK Listing Authority and the London Stock Exchange for a listing of 736,101 ordinary shares, not 300,000 ordinary shares.

The full corrected announcement reads as follows:

Application has been made to the UK Listing Authority and the London Stock Exchange for a listing of 736,101 ordinary shares of 5p each in the Company to be admitted to the Official List.

These shares, ranking pari passu in all respects with the existing shares in issue, have been issued pursuant to the exchange of certain Exchangeable Shares in Shire Acquisition Inc., in accordance with the terms of the Merger Agreement with BioChem Pharma Inc.

T May
Company Secretary
For further information please contact:
Investor Relations	Cléa Rosenfeld (Rest of the world)	+44 1256 894 160
	Brian Piper (North America)	+1 484 595 8252
Notes to editors
Shire Pharmaceuticals Group plc

Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.

For further information on Shire, please visit the Company’s website: www.shire.com.